BioSpace News Archive

CVS to Remove AbbVie’s Humira from Reimbursement Lists, Cover Biosimilars

The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.

January 4, 2024
·
3 min read
·
Tristan Manalac
Business

Roche Inks Potential $2B Deal with MOMA, Continues Early January Hot Streak

In the third deal in as many days, Roche is paying $66 million upfront to MOMA Therapeutics to find new drugs to go after cancer cell growth, with a potential $2 billion total in milestones and royalties.

January 4, 2024
·
3 min read
·
Tyler Patchen
Policy

Pfizer’s Hemophilia B Gene Therapy Wins Approval in Canada, FDA Decision Looms

With a PDUFA date in the second quarter of 2024, Pfizer is poised to compete with CSL Behring, whose Hemgenix became the first FDA-approved gene therapy for hemophilia B in November 2022.

January 4, 2024
·
2 min read
·
Tristan Manalac
Deals

Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics

BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation discuss alternative financing strategies to consider for 2024. Listen now.

January 4, 2024
·
1 min read
·
BioSpace Insights
Drug Development

Phase III Schizophrenia Trial Shows Lyndra’s Weekly Risperidone ‘Comparable’ to J&J’s Daily Risperdal

The late-stage pharmacokinetic study was stopped early due to efficacy at interim analysis, Lyndra Therapeutics said Thursday. A six-month safety study will start in the second half of 2024.

January 4, 2024
·
1 min read
·
Kate Goodwin
Policy

Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit

Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.

January 4, 2024
·
2 min read
·
Tyler Patchen
Business

Novo Deepens Obesity, MASH Expertise in Deals Worth $1B with Two Flagship Biotechs

Novo Nordisk’s partnerships with Flagship Pioneering-backed Omega and Cellarity, each worth up to $532 million, will explore novel treatment approaches to obesity and metabolic dysfunction-associated steatohepatitis.

January 4, 2024
·
2 min read
·
Tristan Manalac
B-Secur Receives ISO 13485:2016 Certification

B-Secur today announced that it has received ISO 13485:2016, the Quality Management System (QMS) for medical devices.

January 4, 2024
·
2 min read
Business

Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.

January 4, 2024
·
13 min read
Pharm Country

Trevi Therapeutics Provides Business Updates

Trevi Therapeutics, Inc. today announced a preview of business updates.

January 4, 2024
·
5 min read